……gets landmark FDA approval By BRONWYN THOMPSON Hugely promising can­cer drug dostarlimab is one step closer to be­ing widely available, after the Food and Drug Administration granted it Breakthrough Ther­apy Designation status that, if successful, will expedite its path to market. Dorstarlimab (brand name Jem­perli) had some remarkable trial results in June, and the results…